The biotechnology industry has long been characterized by astronomical development costs and lengthy timelines that can stretch into decades. Traditional ...

Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas. The symposium, ...

Eva-Maria Hempe, NVIDIA, says bio/pharma must centralize AI strategy, tackle silos, prioritize process integrity, and balance quick wins with long-term drug design goals.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development, ...

Nigel Langley of gChem stresses excipient innovation, safer solvents, and supply chain resilience for pharma’s future in part ...

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients ...

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...

Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...

Renal Cell Carcinoma (RCC): FDA approved oral Everolimus for advanced RCC after failure of sunitinib and/or sorafenib. Approval was based on RECORD-1 randomized phase III (everolimus 10 mg PO daily vs ...

Synopsys, Inc. (NASDAQ: SNPS) is attending NVIDIA GTC Washington, D.C. October 27-29 to showcase advancements in engineering ...

Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings ...